Published in Rheumatology (Oxford) on August 09, 2006
Experience with rituximab in scleroderma: results from a 1-year, proof-of-principle study. Rheumatology (Oxford) (2009) 2.35
Mycophenolate versus cyclophosphamide for progressive interstitial lung disease associated with systemic sclerosis: a 2-year case control study. Lung (2013) 1.43
Systemic sclerosis disease modification clinical trials design: quo vadis? Arthritis Care Res (Hoboken) (2012) 1.39
Evidence-based management of rapidly progressing systemic sclerosis. Best Pract Res Clin Rheumatol (2010) 1.23
Effect of mycophenolate sodium in scleroderma-related interstitial lung disease. Clin Rheumatol (2011) 1.17
High frequency of corticosteroid and immunosuppressive therapy in patients with systemic sclerosis despite limited evidence for efficacy. Arthritis Res Ther (2009) 1.05
Scleroderma lung disease. Eur Respir Rev (2013) 1.04
Immunotherapy of systemic sclerosis. Immunotherapy (2010) 1.03
Mycophenolate mofetil versus oral cyclophosphamide in scleroderma-related interstitial lung disease (SLS II): a randomised controlled, double-blind, parallel group trial. Lancet Respir Med (2016) 1.01
Demographic, clinical and antibody characteristics of patients with digital ulcers in systemic sclerosis: data from the DUO Registry. Ann Rheum Dis (2012) 0.98
Long-term experience of mycophenolate mofetil for treatment of diffuse cutaneous systemic sclerosis. Ann Rheum Dis (2011) 0.96
Effect and safety of mycophenolate mofetil or sodium in systemic sclerosis-associated interstitial lung disease: a meta-analysis. Pulm Med (2012) 0.92
Treatment of early diffuse systemic sclerosis skin disease. Clin Exp Rheumatol (2013) 0.91
Old medications and new targeted therapies in systemic sclerosis. Rheumatology (Oxford) (2014) 0.89
The primary care physician in the early diagnosis of systemic sclerosis: the cornerstone of recognition and hope. Am J Med Sci (2014) 0.87
Management of Systemic-Sclerosis-Associated Interstitial Lung Disease. Rheum Dis Clin North Am (2015) 0.85
Systemic Sclerosis-Associated Interstitial Lung Disease: Lessons from Clinical Trials, Outcome Measures, and Future Study Design. Curr Rheumatol Rev (2010) 0.82
Assessment of tissue fibrosis in skin biopsies from patients with systemic sclerosis employing confocal laser scanning microscopy: an objective outcome measure for clinical trials? Rheumatology (Oxford) (2010) 0.81
Systemic sclerosis: current concepts in pathogenesis and therapeutic aspects of dermatological manifestations. Indian J Dermatol (2013) 0.81
My approach to the treatment of scleroderma. Mayo Clin Proc (2013) 0.81
Safety and effectiveness of mycophenolate in systemic sclerosis. A systematic review. PLoS One (2015) 0.81
Recent Treatments of Interstitial Lung Disease with Systemic Sclerosis. Clin Med Insights Circ Respir Pulm Med (2016) 0.78
Treatment of Systemic Sclerosis-related Interstitial Lung Disease: A Review of Existing and Emerging Therapies. Ann Am Thorac Soc (2016) 0.78
Treatment of Rapidly Progressive Systemic Sclerosis: Current and Futures Perspectives. Expert Opin Orphan Drugs (2015) 0.77
Early onset neutropenia after mycophenolate mofetil in systemic sclerosis. Rheumatol Int (2009) 0.76
Enteric-coated mycophenolate sodium for progressive systemic sclerosis--a prospective open-label study with CT histography for monitoring of pulmonary fibrosis. Clin Rheumatol (2013) 0.76
Scleroderma therapy: clinical overview of current trends and future perspective. Rheumatol Int (2012) 0.76
The emergence of mycophenolate mofetilin dermatology: from its roots in the world of organ transplantation to its versatile role in the dermatology treatment room. J Clin Aesthet Dermatol (2011) 0.75
Cyclophosphamide versus mycophenolate mofetil in scleroderma interstitial lung disease (SSc-ILD) as induction therapy: a single-centre, retrospective analysis. Arthritis Res Ther (2016) 0.75
Application of the 2013 ACR/EULAR classification criteria for systemic sclerosis to patients with Raynaud's phenomenon. Arthritis Res Ther (2015) 0.75
Lung Transplantation for Scleroderma-related Lung Disease. Curr Respir Care Rep (2014) 0.75
Mycophenolate versus Placebo for Systemic Sclerosis-Related Interstitial Lung Disease: An Analysis of Scleroderma Lung Studies I and II. Arthritis Rheumatol (2017) 0.75
[Towards an implementation of guidelines for the therapy of systemic sclerosis (scleroderma): between desire and reality]. Z Rheumatol (2010) 0.75
Digital ulcers in systemic sclerosis: prevention by treatment with bosentan, an oral endothelin receptor antagonist. Arthritis Rheum (2004) 3.46
CTGF and SMADs, maintenance of scleroderma phenotype is independent of SMAD signaling. J Biol Chem (2001) 3.28
Echocardiography and pulmonary function as screening tests for pulmonary arterial hypertension in systemic sclerosis. Rheumatology (Oxford) (2004) 3.12
Evaluation of polymerase chain reaction for diagnosis of pneumococcal pneumonia. J Clin Microbiol (1993) 3.04
Family study of the major histocompatibility complex in patients with systemic lupus erythematosus: importance of null alleles of C4A and C4B in determining disease susceptibility. Br Med J (Clin Res Ed) (1983) 2.86
Prevalence and outcome in systemic sclerosis associated pulmonary arterial hypertension: application of a registry approach. Ann Rheum Dis (2003) 2.85
A disease severity scale for systemic sclerosis: development and testing. J Rheumatol (1999) 2.85
Circulating endothelin-1 levels in systemic sclerosis subsets--a marker of fibrosis or vascular dysfunction? J Rheumatol (1994) 2.76
The specificity of fetal IgM: antibody or anti-antibody? Ann N Y Acad Sci (1975) 2.65
Antibody-dependent cell-mediated cytotoxicity to target cells infected with type 1 and type 2 herpes simplex virus. J Immunol (1976) 2.49
European multicentre study to define disease activity criteria for systemic sclerosis. II. Identification of disease activity variables and development of preliminary activity indexes. Ann Rheum Dis (2001) 2.49
The promise of integrated representative surveys about sexually transmitted diseases and behavior. Sex Transm Dis (1997) 2.44
Randomized, prospective, placebo-controlled trial of bosentan in interstitial lung disease secondary to systemic sclerosis. Arthritis Rheum (2010) 2.37
Association of phenotypic and genotypic characteristics of invasive Streptococcus pyogenes isolates with clinical components of streptococcal toxic shock syndrome. Infect Immun (1993) 2.32
Bosentan treatment for pulmonary arterial hypertension related to connective tissue disease: a subgroup analysis of the pivotal clinical trials and their open-label extensions. Ann Rheum Dis (2006) 2.28
Evaluation of bias in diagnostic-test sensitivity and specificity estimates computed by discrepant analysis. J Clin Microbiol (1998) 2.14
Scleroderma renal crisis: patient characteristics and long-term outcomes. QJM (2007) 2.14
Role of superoxide dismutase and catalase as determinants of pathogenicity of Nocardia asteroides: importance in resistance to microbicidal activities of human polymorphonuclear neutrophils. Infect Immun (1985) 2.06
Evaluation of nucleic acid amplification tests as reference tests for Chlamydia trachomatis infections in asymptomatic men. J Clin Microbiol (2000) 2.02
Comparison of Doppler echocardiography and right heart catheterization to assess pulmonary hypertension in systemic sclerosis. Br J Rheumatol (1997) 2.00
Multiple drug-resistant Chlamydia trachomatis associated with clinical treatment failure. J Infect Dis (2000) 1.89
Childhood-onset scleroderma: is it different from adult-onset disease. Arthritis Rheum (1996) 1.85
Imatinib for the treatment of refractory, diffuse systemic sclerosis. Rheumatology (Oxford) (2008) 1.83
Measurement and characterisation of circulating anti-endothelial cell IgG in connective tissue diseases. Clin Exp Immunol (1988) 1.83
Comparison of arbitrarily primed polymerase chain reaction, ribotyping, and monoclonal antibody analysis for subtyping Legionella pneumophila serogroup 1. J Clin Microbiol (1993) 1.82
Treatment of Raynaud's phenomenon with the selective serotonin reuptake inhibitor fluoxetine. Rheumatology (Oxford) (2001) 1.82
Interferon-alpha does not improve outcome at one year in patients with diffuse cutaneous scleroderma: results of a randomized, double-blind, placebo-controlled trial. Arthritis Rheum (1999) 1.79
A pilot study of the prevalence of chlamydial infection in a national household survey. Sex Transm Dis (1998) 1.78
Immunogenetic prediction of pulmonary fibrosis in systemic sclerosis. Lancet (1991) 1.76
Treatment of systemic vasculitis with pooled intravenous immunoglobulin. Lancet (1991) 1.76
Tumor necrosis factor alpha suppresses the induction of connective tissue growth factor by transforming growth factor-beta in normal and scleroderma fibroblasts. J Biol Chem (2000) 1.74
Systemic sclerosis associated pulmonary hypertension: improved survival in the current era. Heart (2005) 1.73
Evaluation of thirty-one mouse monoclonal antibodies to human IgG epitopes. Hybridoma (1984) 1.67
Anti-RNA polymerases and other autoantibody specificities in systemic sclerosis. Br J Rheumatol (1998) 1.66
Pilot study of anti-thymocyte globulin plus mycophenolate mofetil in recent-onset diffuse scleroderma. Rheumatology (Oxford) (2001) 1.66
The source and role of RANTES in interstitial lung disease. Eur Respir J (1997) 1.62
Typing of Chlamydia trachomatis strains from urine samples by amplification and sequencing the major outer membrane protein gene (omp1). Sex Transm Infect (2001) 1.62
Serological markers in progressive systemic sclerosis: clinical correlations. Ann Rheum Dis (1983) 1.55
Immunohistochemical localization of transforming growth factor-beta 1 in the lungs of patients with systemic sclerosis, cryptogenic fibrosing alveolitis and other lung disorders. Histopathology (1994) 1.54
The use of infra-red thermography in a rheumatology unit. Br J Rheumatol (1990) 1.53
Fibroblast matrix gene expression and connective tissue remodeling: role of endothelin-1. J Invest Dermatol (2001) 1.51
Fibrosing alveolitis associated with systemic sclerosis has a better prognosis than lone cryptogenic fibrosing alveolitis. Am J Respir Crit Care Med (1994) 1.49
Increased levels of endothelin-1 and differential endothelin type A and B receptor expression in scleroderma-associated fibrotic lung disease. Am J Pathol (1997) 1.47
Doxycycline and azithromycin for prevention of chlamydial persistence or recurrence one month after treatment in women. A use-effectiveness study in public health settings. Sex Transm Dis (1998) 1.46
Prediction of five-year survival following presentation with scleroderma: development of a simple model using three disease factors at first visit. Arthritis Rheum (1999) 1.45
Progress in systemic sclerosis: a 10-year perspective. Rheumatology (Oxford) (2009) 1.44
Clearance of inhaled technetium-99m-DTPA as a clinical index of pulmonary vascular disease in systemic sclerosis. Eur Respir J (1999) 1.44
Suppression of endogenous IL-10 gene expression in dendritic cells enhances antigen presentation for specific Th1 induction: potential for cellular vaccine development. J Immunol (2000) 1.42
Structural features of interstitial lung disease in systemic sclerosis. Am Rev Respir Dis (1991) 1.41
Antireticulin antibody in systemic sclerosis. Ann Rheum Dis (1990) 1.40
Iloprost suppresses connective tissue growth factor production in fibroblasts and in the skin of scleroderma patients. J Clin Invest (2001) 1.39
Five patients who developed systemic sclerosis shortly after episodes of physical trauma. J Rheumatol (1996) 1.38
Anti-PL 4 in patients with systemic lupus erythematosus with severe renal and haematological disease. QJM (1997) 1.38
Enzyme immunoassay to determine exposure to Chlamydia pneumoniae (strain TWAR). J Clin Microbiol (1989) 1.37
Pulmonary hypertension in systemic sclerosis: risk factors for progression and consequences for survival. Rheumatology (Oxford) (2001) 1.35
IgG antiendothelial cell autoantibodies from scleroderma patients induce leukocyte adhesion to human vascular endothelial cells in vitro. Induction of adhesion molecule expression and involvement of endothelium-derived cytokines. J Clin Invest (1996) 1.34
Addition of monoclonal antibodies specific for Rickettsia akari to the rickettsial diagnostic panel. J Clin Microbiol (1988) 1.32
European Scleroderma Study Group to define disease activity criteria for systemic sclerosis. III. Assessment of the construct validity of the preliminary activity criteria. Ann Rheum Dis (2003) 1.32
Role of thrombin in pulmonary fibrosis. Lancet (1995) 1.30
Autocrine overexpression of CTGF maintains fibrosis: RDA analysis of fibrosis genes in systemic sclerosis. Exp Cell Res (2000) 1.30
Route of infection that induces a high intensity of gamma interferon-secreting T cells in the genital tract produces optimal protection against Chlamydia trachomatis infection in mice. Infect Immun (1998) 1.29
Clearance of inhaled 99mTc-DTPA predicts the clinical course of fibrosing alveolitis. Eur Respir J (1993) 1.29
Acidification of phagosomes in murine macrophages: blockage by Nocardia asteroides. J Infect Dis (1986) 1.29
Digital ulcers: overt vascular disease in systemic sclerosis. Rheumatology (Oxford) (2009) 1.29
N-terminal connective tissue growth factor is a marker of the fibrotic phenotype in scleroderma. QJM (2005) 1.28
In vivo and in vitro activation of alveolar macrophages by recombinant interferon-gamma. J Immunol (1987) 1.28
The predictive value of appearances on thin-section computed tomography in fibrosing alveolitis. Am Rev Respir Dis (1993) 1.28
Development of a provisional core set of response measures for clinical trials of systemic sclerosis. Ann Rheum Dis (2007) 1.26
Mycoplasma contamination of chlamydiae isolated from clinical specimens. APMIS (1994) 1.24
The control of ccn2 (ctgf) gene expression in normal and scleroderma fibroblasts. Mol Pathol (2001) 1.24
High resolution computed tomography as a predictor of lung histology in systemic sclerosis. Thorax (1992) 1.23
Detection and characterization of mouse monoclonal antibodies to epidemic typhus rickettsiae. J Clin Microbiol (1983) 1.21
Screening high-risk adolescent males for Chlamydia trachomatis infection. Obtaining urine specimens in the field. Sex Transm Dis (1998) 1.21
Microtubule nucleating sites in higher plant cells identified by an auto-antibody against pericentriolar material. J Cell Biol (1985) 1.21
A double blind, randomised, multicentre comparison of two doses of intravenous iloprost in the treatment of Raynaud's phenomenon secondary to connective tissue diseases. Ann Rheum Dis (1991) 1.20
Genetic susceptibility to scleroderma-like syndrome induced by vinyl chloride. Lancet (1983) 1.20
The clinical and immunogenetic features of patients with autoantibodies to the nucleolar antigen PM-Scl. Medicine (Baltimore) (1992) 1.20
Detection of Neisseria gonorrhoeae infection by ligase chain reaction testing of urine among adolescent women with and without Chlamydia trachomatis infection. Sex Transm Dis (1998) 1.19
Rapid assessment of sexually transmitted diseases in a sentinel population in Thailand: prevalence of chlamydial infection, gonorrhoea, and syphilis among pregnant women--1996. Sex Transm Infect (1998) 1.18
Localisation of transforming growth factor beta1 and beta3 mRNA transcripts in normal and fibrotic human lung. Thorax (2001) 1.18
Effect of virulent and less virulent strains of Nocardia asteroides on acid-phosphatase activity in alveolar and peritoneal macrophages maintained in vitro. J Infect Dis (1983) 1.17
Thyroid-stimulating antibody activity between different immunoglobulin G subclasses. J Clin Invest (1990) 1.17
Systemic sclerosis: an autoantibody mosaic. Clin Exp Immunol (1999) 1.17
Increased levels of endothelin-1 in bronchoalveolar lavage fluid from patients with systemic sclerosis contribute to fibroblast mitogenic activity in vitro. Am J Respir Cell Mol Biol (1994) 1.16
Activation of microvascular pericytes in autoimmune Raynaud's phenomenon and systemic sclerosis. Arthritis Rheum (1999) 1.15
Different cytokine profiles in cryptogenic fibrosing alveolitis and fibrosing alveolitis associated with systemic sclerosis: a quantitative study of open lung biopsies. Eur Respir J (1999) 1.15
Patterns and predictors of change in outcome measures in clinical trials in scleroderma: an individual patient meta-analysis of 629 subjects with diffuse cutaneous systemic sclerosis. Arthritis Rheum (2012) 1.13
Affinity purification of IgG subclasses and the distribution of thyroid auto-antibody reactivity in Hashimoto's thyroiditis. Scand J Immunol (1989) 1.12
Serial circulating adhesion molecule levels reflect disease severity in systemic sclerosis. Br J Rheumatol (1995) 1.12
Pulmonary involvement in systemic sclerosis: the detection of early changes by thin section CT scan, bronchoalveolar lavage and 99mTc-DTPA clearance. Respir Med (1989) 1.11
Behaviors associated with Neisseria gonorrhoeae and Chlamydia trachomatis: cervical infection among young women attending adolescent clinics. Clin Pediatr (Phila) (2000) 1.11
Predictors of end stage lung disease in a cohort of patients with scleroderma. Ann Rheum Dis (2003) 1.10